Prolongation of allograft survival by combination therapy with anti-thymocyte serum and anti-immunoglobulin.
Heterologous anti-immunoglobulin (AI) is a potent immunosuppressive agent which compares favorably to anti-thymocyte serum (ATS) in inhibiting E and EAC-rosette formation and diminishing the secondary antibody response to sheep erythrocytes and E. coli lipopolysaccharide. AI prolongs H-2 incompatible skin allograft survival than either antiserum used alone, without evidence of toxicity to recipient mice. AI does not cause significant immune complex glomerular or renovascular deposition and may act by interference with antigen binding.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000936:Antigen-Antibody Complex; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001666:Binding Sites, Antibody; D004912:Erythrocytes / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology; D006462:Hemolytic Plaque Technique; D007104:Immune Adherence Reaction; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011817:Rabbits; D012756:Sheep; D016038:Skin Transplantation; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D000936:Antigen-Antibody Complex; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides